Clinical Trial Update: Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether zoledronic acid added to letrozole can mitigate cancer treatment–related bone loss in postmenopausal women with ER+/PR+ breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Osteoporosis

Drugs mentioned

• Letrozole (letrozole)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Neoplasms, Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2014-01-28